AgingResearch.NewsJoin free
medRxiv

Starting metformin linked to slightly higher severe COVID-19 risk

Starting metformin was linked to a 0.36-percentage-point higher two-year risk of COVID-19 hospitalization or death than starting no diabetes drug.

Paper by A. Amstutz, V. Walker, P. Madley-Dowd, +6 more authorsJ. A. C. Sterne · University of Basel: Universitat Basel
Upright blue-green and gray figures stand beside lungs with larger and smaller dark patches, with a small molecular shape beside the blue-green group.

Our read

Interventions
Studied:
Preprint: cohort study of 52,341 adults newly diagnosed with type 2 diabetes, up to 2 years
What changed:
Metformin starters had a 0.36-percentage-point higher two-year risk of COVID-19 hospitalization or death than people starting no diabetes drug
The catch:
Higher diabetes-related mortality suggests metformin starters had worse underlying diabetes risk
In the record:
The 741st paper on metformin with results in people; 2,326 on record in all.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper
Follow @agingbrief

Among 52,341 adults aged 18–85 newly diagnosed with type 2 diabetes in England, a population-based cohort study compared starting metformin with starting no diabetes drug. Researchers used linked NHS health records. Within six months of diagnosis, 19,599 people started metformin alone. Follow-up began six months after diagnosis, before the UK pandemic, and lasted up to two years.

Starting metformin was linked to a slightly higher risk of COVID-19 hospitalization or death. The long COVID estimate was uncertain: the range of likely values included no difference. Diabetes-related deaths were also more frequent among metformin starters. The authors said this finding indicated unmeasured differences between the groups and that such differences plausibly explained the COVID-19 results.

Why it matters

Type 2 diabetes is an age-related disease. These results address whether starting a diabetes medicine also offers protection against COVID-19.

Caveats

People prescribed metformin may have differed in unmeasured ways from those starting no diabetes drug. This preprint has not been peer-reviewed, and its findings concern newly diagnosed diabetes rather than long-term metformin use.

Where the evidence stands

Metformin

Cells, worms or flies, mice and humans: replicated by independent labs.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 567 independent labs in 69 countries
  • 262 findings against
  • 1,398 trials, 569 with no results posted
  • Funders: National Institutes of Health and others
  • 177 of 2,651 findings with company ties
  • 38 of 1,398 trials sponsored by its developers

Comments

Be the first to comment.

Metformin is part of Bryan Johnson's Blueprint and David Sinclair's daily regimen in Lifespan

More on Metformin